|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:affiliatedWith
|
phosphodiesterase type 5 inhibitor
|
|
gptkbp:approvedBy
|
1998
|
|
gptkbp:ATCCode
|
gptkb:G04BE03
|
|
gptkbp:CASNumber
|
gptkb:144689-63-4
|
|
gptkbp:contraindication
|
nitrate medications
|
|
gptkbp:developedBy
|
gptkb:United_Kingdom
|
|
gptkbp:discoveredBy
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C22H30N6O4S
|
|
gptkbp:hasSMILES
|
CCN1CCN(CC1)S(=O)(=O)C2=CC(=C(C=C2)N3C=NC4=C3N=C(NC4C)CCC)OCC.C6H8O7
|
|
gptkbp:hasUNII
|
3M7OB98Y7H
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
144689-63-4
|
|
gptkbp:IUPACName
|
1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
666.7 g/mol (citrate salt)
|
|
gptkbp:name
|
Sildenafil citrate
|
|
gptkbp:PubChem_CID
|
CHEMBL192
DB00203
135398744
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
headache
dyspepsia
flushing
visual disturbances
|
|
gptkbp:synonym
|
gptkb:Revatio
gptkb:Viagra
|
|
gptkbp:usedFor
|
erectile dysfunction
pulmonary arterial hypertension
|
|
gptkbp:bfsParent
|
gptkb:olmesartan
gptkb:Olmesartan
|
|
gptkbp:bfsLayer
|
7
|